EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes

Elizabeth Hastie iD, Megha Srivasta, Edward R Cachay, Leah Burke, Sara Gianella, Stephen Rawlings, Frank Z Stanczyk, Craig Sykes, Angela D M Kashuba, Jill Blumenthal, Mackenzie L Cottrell

British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2949-2959

DOI: 10.1002/bcp.70586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 07.05.2026. Verfasst von Elizabeth Hastie und 10 weiteren Autor:innen. Beteiligte Einrichtung: University of California San Diego, San Diego, California, USA. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Pre-Exposure Prophylaxis, HIV Infections, Transgender Persons. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Female sex hormones used in feminizing hormone therapy (FHT) may influence activation and persistence of HIV pre‐exposure prophylaxis (PrEP) medications. The clinical relevance of this interaction remains unclear, particularly for transgender and cisgender women (TGW and CGW). To address this gap, we examined drug metabolites in HIV susceptible cells isolated from blood and rectal tissues of TGW and CGW. Materials and Methods We enrolled 23 TGW, 13 on FHT and 10 CGW. Participants received five directly observed daily PrEP doses: emtricitabine 200 mg with either tenofovir disoproxil fumarate 300 mg (FTC/TDF) or tenofovir alafenamide 25 mg (FTC/TAF). Blood and rectal tissue samples were obtained. Mononuclear and CD4 + cells were isolated and analysed for intracellular triphosphorylated nucleotides (TFVdp and FTCtp) and total nucleotide pools (pTFV and pFTC) using HPLC‐MS/MS. Serum hormone concentrations were quantified via enzyme immunoassay. Results and Conclusion Total nucleotide pools (pTFV and pFTC) correlated with active metabolites (TFVdp and FTCtp) in blood and rectal CD4 + cells ( r 2 > 0.75, p < .001). No significant differences in pTFV or pFTC concentrations were observed between high and low oestradiol groups in either CGW or TGW ( p > .1). No correlation was observed between serum oestradiol concentrations and nucleotide concentrations. TAF resulted in 6.8‐fold higher median pTFV concentrations in blood CD4 + cells ( p < .001) but eightfold lower median pTFV concentrations in rectal CD4 + cells compared to TDF ( p = .008). These findings suggest that neither endogenous hormonal fluctuations in CGW nor exogenous FHT in TGW adversely impact intracellular PrEP pharmacology in key HIV target cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD4-Positive T-LymphocytesPre-Exposure ProphylaxisHIV InfectionsTransgender PersonsAnti-HIV AgentsHumansFemaleAdultMaleRectumTenofovirMiddle AgedYoung AdultAlanineGonadal Steroid HormonesAdenineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationNucleotides

Stichwörter der Autor:innen

HIVfeminizing hormone therapylower gastrointestinal tractpre‐exposure prophylaxistransgender

Substanzen

Anti-HIV AgentsTenofovirtenofovir alafenamideAlanineGonadal Steroid HormonesAdenineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationNucleotides

Autor:innen und Institutionen

  • University of California San Diego, San Diego, California, USA.
  • Mayo Clinic, Rochester, Minnesota, USA.
  • Maine Medical Center, Portland, Maine, USA.
  • University of Southern California, Los Angeles, California, USA.
  • University of North Carolina, Chapel Hill, North Carolina, USA.

ORCID-Profile: Elizabeth Hastie

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Hastie, E., Srivasta, M., Cachay, E. R., Burke, L., Gianella, S., Rawlings, S., Stanczyk, F. Z., Sykes, C., Kashuba, A. D. M., Blumenthal, J., & Cottrell, M. L. (2026). PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes. British Journal of Clinical Pharmacology, 92(8), 2949-2959. https://doi.org/10.1002/bcp.70586

Vancouver

Hastie E, Srivasta M, Cachay ER, Burke L, Gianella S, Rawlings S, et al. PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes. British Journal of Clinical Pharmacology. 2026;92(8):2949-2959. doi:10.1002/bcp.70586

BibTeX
@article{Hastie2026,
  author = {Hastie, Elizabeth and Srivasta, Megha and Cachay, Edward R and Burke, Leah and Gianella, Sara and Rawlings, Stephen and Stanczyk, Frank Z and Sykes, Craig and Kashuba, Angela D M and Blumenthal, Jill and Cottrell, Mackenzie L},
  title = {PrEP at the site of action in cisgender and transgender women: A pharmacology study of blood and rectal CD4 + lymphocytes},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {8},
  pages = {2949--2959},
  doi = {10.1002/bcp.70586}
}
Kostenlos starten →